Literature DB >> 19910347

Association of race, substance abuse, and health insurance coverage with use of highly active antiretroviral therapy among HIV-infected women, 2005.

Marsha Lillie-Blanton1, Valerie E Stone, Alison Snow Jones, Jeffrey Levi, Elizabeth T Golub, Mardge H Cohen, Nancy A Hessol, Tracey E Wilson.   

Abstract

OBJECTIVES: We examined racial/ethnic disparities in highly active antiretroviral therapy (HAART) use and whether differences are moderated by substance use or insurance status, using data from the Women's Interagency HIV Study (WIHS).
METHODS: Logistic regression examined HAART use in a longitudinal cohort of women for whom HAART was clinically indicated in 2005 (N = 1354).
RESULTS: Approximately 3 of every 10 eligible women reported not taking HAART. African American and Hispanic women were less likely than were White women to use HAART. After we adjusted for potential confounders, the higher likelihood of not using HAART persisted for African American but not for Hispanic women. Uninsured and privately insured women, regardless of race/ethnicity, were less likely than were Medicaid enrollees to use HAART. Although alcohol use was related to HAART nonuse, illicit drug use was not.
CONCLUSIONS: These findings suggest that expanding and improving insurance coverage should increase access to antiretroviral therapy across racial/ethnic groups, but it is not likely to eliminate the disparity in use of HAART between African American and White women with HIV/AIDS.

Entities:  

Mesh:

Year:  2009        PMID: 19910347      PMCID: PMC2901300          DOI: 10.2105/AJPH.2008.158949

Source DB:  PubMed          Journal:  Am J Public Health        ISSN: 0090-0036            Impact factor:   9.308


  17 in total

1.  Combination antiretroviral therapy: health care providers confront emerging dilemmas.

Authors:  B Gerbert; A Bronstone; K Clanon; P Abercrombie; D Bangsberg
Journal:  AIDS Care       Date:  2000-08

2.  Prevalence and predictors of highly active antiretroviral therapy use in patients with HIV infection in the united states. HCSUS Consortium. HIV Cost and Services Utilization.

Authors:  W E Cunningham; L E Markson; R M Andersen; S H Crystal; J A Fleishman; C Golin; A Gifford; H H Liu; T T Nakazono; S Morton; S A Bozzette; M F Shapiro; N S Wenger
Journal:  J Acquir Immune Defic Syndr       Date:  2000-10-01       Impact factor: 3.731

3.  Factors influencing physicians' judgments of adherence and treatment decisions for patients with HIV disease.

Authors:  L M Bogart; S L Catz; J A Kelly; E G Benotsch
Journal:  Med Decis Making       Date:  2001 Jan-Feb       Impact factor: 2.583

4.  Association of medical insurance and other factors with receipt of antiretroviral therapy.

Authors:  Jeanne C Keruly; Richard Conviser; Richard D Moore
Journal:  Am J Public Health       Date:  2002-05       Impact factor: 9.308

5.  Health and federal budgetary effects of increasing access to antiretroviral medications for HIV by expanding Medicaid.

Authors:  J G Kahn; B Haile; J Kates; S Chang
Journal:  Am J Public Health       Date:  2001-09       Impact factor: 9.308

6.  Relation of physician specialty and HIV/AIDS experience to choice of guideline-recommended antiretroviral therapy.

Authors:  V E Stone; F F Mansourati; R M Poses; K H Mayer
Journal:  J Gen Intern Med       Date:  2001-06       Impact factor: 5.128

7.  Use of highly active antiretroviral therapy in a cohort of HIV-seropositive women.

Authors:  Judith A Cook; Mardge H Cohen; Dennis Grey; Lynn Kirstein; Jane Burke; Kathryn Anastos; Herminia Palacio; Jean Richardson; Tracey E Wilson; Mary Young
Journal:  Am J Public Health       Date:  2002-01       Impact factor: 9.308

8.  Impact of medical and nonmedical factors on physician decision making for HIV/AIDS antiretroviral treatment.

Authors:  L M Bogart; J A Kelly; S L Catz; J M Sosman
Journal:  J Acquir Immune Defic Syndr       Date:  2000-04-15       Impact factor: 3.731

9.  Black-White mortality from HIV in the United States before and after introduction of highly active antiretroviral therapy in 1996.

Authors:  Robert S Levine; Nathaniel C Briggs; Barbara S Kilbourne; William D King; Yvonne Fry-Johnson; Peter T Baltrus; Baqar A Husaini; George S Rust
Journal:  Am J Public Health       Date:  2007-08-29       Impact factor: 9.308

10.  Medically eligible women who do not use HAART: the importance of abuse, drug use, and race.

Authors:  Mardge H Cohen; Judith A Cook; Dennis Grey; Mary Young; Lawrence H Hanau; Phyllis Tien; Alexandra M Levine; Tracey E Wilson
Journal:  Am J Public Health       Date:  2004-07       Impact factor: 9.308

View more
  40 in total

1.  Disparities in antiretroviral treatment: a comparison of behaviorally HIV-infected youth and adults in the HIV Research Network.

Authors:  Allison L Agwu; John A Fleishman; P Todd Korthuis; George K Siberry; Jonathan M Ellen; Aditya H Gaur; Richard Rutstein; Kelly A Gebo
Journal:  J Acquir Immune Defic Syndr       Date:  2011-09-01       Impact factor: 3.731

2.  Operationalizing treatment as prevention in Los Angeles County: antiretroviral therapy use and factors associated with unsuppressed viral load in the Ryan White system of care.

Authors:  Jennifer N Sayles; Jacqueline Rurangirwa; Min Kim; Janni Kinsler; Rangell Oruga; Mike Janson
Journal:  AIDS Patient Care STDS       Date:  2012-07-09       Impact factor: 5.078

3.  High levels of antiretroviral use and viral suppression among persons in HIV care in the United States, 2010.

Authors:  Julia C Dombrowski; Mari M Kitahata; Stephen E Van Rompaey; Heidi M Crane; Michael J Mugavero; Joseph J Eron; Stephen L Boswell; Benigno Rodriguez; W Christopher Mathews; Jeffrey N Martin; Richard D Moore; Matthew R Golden
Journal:  J Acquir Immune Defic Syndr       Date:  2013-07-01       Impact factor: 3.731

4.  Risk factors for short-term virologic outcomes among HIV-infected patients undergoing regimen switch of combination antiretroviral therapy.

Authors:  Chun Chao; Beth Tang; Leo Hurley; Michael J Silverberg; William Towner; Melissa Preciado; Michael Horberg
Journal:  AIDS Res Hum Retroviruses       Date:  2012-04-27       Impact factor: 2.205

5.  Trends in Racial/Ethnic Disparities Among Patients Living with HIV in Texas, 1996 to 2013.

Authors:  Sabina O Nduaguba; Kentya H Ford; James P Wilson; Kenneth A Lawson
Journal:  J Racial Ethn Health Disparities       Date:  2017-12-21

6.  Multi-dimensional risk factor patterns associated with non-use of highly active antiretroviral therapy among human immunodeficiency virus-infected women.

Authors:  Alison Snow Jones; Marsha Lillie-Blanton; Valerie E Stone; Edward H Ip; Qiang Zhang; Tracey E Wilson; Mardge H Cohen; Elizabeth T Golub; Nancy A Hessol
Journal:  Womens Health Issues       Date:  2010-06-25

Review 7.  A Critical Review and Commentary on the Challenges in Engaging HIV-Infected Latinos in the Continuum of HIV Care.

Authors:  Julie H Levison; Julia K Levinson; Margarita Alegría
Journal:  AIDS Behav       Date:  2018-08

8.  Association Between Depression and Antiretroviral Therapy Use Among People Living with HIV: A Meta-analysis.

Authors:  Jun Tao; Sten H Vermund; Han-Zhu Qian
Journal:  AIDS Behav       Date:  2018-05

9.  Trends and disparities in antiretroviral therapy initiation and virologic suppression among newly treatment-eligible HIV-infected individuals in North America, 2001-2009.

Authors:  David B Hanna; Kate Buchacz; Kelly A Gebo; Nancy A Hessol; Michael A Horberg; Lisa P Jacobson; Gregory D Kirk; Mari M Kitahata; P Todd Korthuis; Richard D Moore; Sonia Napravnik; Pragna Patel; Michael J Silverberg; Timothy R Sterling; James H Willig; Bryan Lau; Keri N Althoff; Heidi M Crane; Ann C Collier; Hasina Samji; Jennifer E Thorne; M John Gill; Marina B Klein; Jeffrey N Martin; Benigno Rodriguez; Sean B Rourke; Stephen J Gange
Journal:  Clin Infect Dis       Date:  2013-01-11       Impact factor: 9.079

Review 10.  ART uptake and adherence among women who use drugs globally: A scoping review.

Authors:  Jennifer L Glick; Aimee Huang; Rienna Russo; Belinda Jivapong; Vijayasundaram Ramasamy; Lori Rosman; Danielle Pelaez; Katherine H A Footer; Susan G Sherman
Journal:  Drug Alcohol Depend       Date:  2020-08-02       Impact factor: 4.492

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.